ABSTRACT
To achieve glycemic goals in type 2 diabetes, one must usually use combinations of oral agents or oral agents plus insulin. This paper discusses the metabolic derangements of type 2 diabetes, the different classes of antihyperglycemic drugs, and strategies for using these drugs rationally.
Footnotes
↵* The author has indicated that he has received grant or research support from the Bristol-Myers Squibb, GlaxoSmithKline, and Novo Nordisk corporations; serves as a consultant for the Amylin, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Merck-Lipha, Novartis, Novo Nordisk, Pfizer, and Takeda corporations; is on the speakers’ bureaus of all of the above plus the Aventis corporation; and is a major stock shareholder in the Bayer, Bristol-Myers Squibb, and GlaxoSmithKline corporations.
- Copyright © 2002 The Cleveland Clinic Foundation. All Rights Reserved.